Financial Contrast: Progyny (NASDAQ:PGNY) and Zhongchao (NASDAQ:ZCMD)

Progyny (NASDAQ:PGNY) and Zhongchao (NASDAQ:ZCMD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Progyny and Zhongchao’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Zhongchao	N/A	N/A	N/A

Earnings & Valuation

This table compares Progyny and Zhongchao”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29 billion	1.56	$58.52 million	$0.92	28.55
Zhongchao	$11.38 million	0.11	-$6.31 million	N/A	N/A

Progyny has higher revenue and earnings than Zhongchao.

Analyst Ratings

This is a summary of recent ratings and price targets for Progyny and Zhongchao, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	3	8	1	2.83
Zhongchao	1	0	0	0	1.00

Progyny presently has a consensus target price of $34.10, suggesting a potential upside of 29.81%. Given Progyny’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Progyny is more favorable than Zhongchao.

Volatility and Risk

Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Zhongchao has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500.

Institutional and Insider Ownership

94.9% of Progyny shares are owned by institutional investors. Comparatively, 1.7% of Zhongchao shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 28.6% of Zhongchao shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Progyny beats Zhongchao on 12 of the 13 factors compared between the two stocks.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.